spacer
home > epc > Winter 2013
PUBLICATIONS

European Pharmaceutical Contractor

epc
Winter 2013

   
Text
PDF
bullet
Marketplace & Business
Emerging Markets

Outsourcing Opportunities

CROs are increasingly looking to the Middle East, Europe and Africa to satisfy their outsourcing needs. Adam M Dion at GlobalData Healthcare demonstrates the advantages that these regions hold, with examples from this year’s activity.


 
view
download pdf
CRO Collaborations

Selection Principles


In order to overcome the obstacles in clinical study partner selection, companies must implement a rigorous strategy. Michel Hantzperg at ICTA Systems says the pharmaceutical industry could learn from historic military tactics.
 
view
download pdf
bullet
Legal & Regulatory

Ethical Issues

Code of Conduct

Ghanashyam Rao and Indu Singh at ELC Group explain how it is essential to ensure ethical conduct is adhered to in clinical research – and discuss why study design and informed consent are just a small part of the challenge.

 
view
download pdf
Research Misconduct

False Evidence

As paper retractions in scientific journals continue to rise, Martin Robinson at IAoCR assesses how education and training of employees is critical in avoiding research misconduct.
 
view
download pdf
Anti-Bribery Legislation

Company Compliance


Samantha Regenthal at SFL Regulatory Affairs & Scientific Communication Ltd reveals why compliance training has been brought to the fore, as alleged corrupt business practices emerge.
 
view
download pdf
bullet
Drug Development & Delivery

Medical Device Outsourcing

In Demand

Karyn Korieth at CenterWatch illustrates how medical device companies can use CROs in development work. By reducing rising costs, companies are able to expand into the global market at a faster pace.

 
view
download pdf
Combination Products

Testing Times

Global inconsistencies in testing regulations and reimbursement problems are creating challenges for the development of combination products. DivyaaRavishankar at Frost & Sullivan explains.
 
view
download pdf
Companion Diagnostics

Supporting Role

At the core of the shift towards personalised medicine are companion diagnostics. Mark Roberts at Covance suggests that the ideal partners in the co-development process are contract research organisations.
 
view
download pdf
bullet
Drug Discovery, Development & Delivery
Pharmacokinetic Equivalence

Equal Measures


In biosimilar trials, proving the pharmacokinetic equivalence of biologics can be a diffi cult task. Yvonne Moores at Quanticate suggests ways to resolve this pressing issue.
 
view
download pdf
bullet
Patient Recruitment
Patient Access Programmes

Think Global

Mark Corbett at Clinigen discusses why pharma companies worldwide should consider implementing global access programmes in cases where therapeutic options may not be readily available.
 
view
download pdf
bullet
Data Management & IT Solutions
Cloud-Based Computing

Silver Linings

Denise Oakley at GXS outlines how cloud-based computing can aid global pharma companies in distinguishing themselves from the competition.
 
view
download pdf
bullet
Review
Annual Review

The CRO Scene

EPC Editor Graham Hughes reports on the latest developments of the CRO market, and gives an insight into the industry’s future.
 
view
download pdf
In Conclusion

Tourist Attraction

Graham Hughes reflects on the contradictory accusations of health services around the globe.

 
view
download pdf
bullet
Commercial & Regulatory
Regulatory Personnel

Talent Pool

The industry is becoming increasingly focused on recruiting a new ‘super-breed’ of employees. Susan Macdonald at RSA considers ways to attract and retain these prized employees.
 
view
download pdf

Interview

Industry Interview

Client Focused

David Spaight of WIL Research talks to EPC about his business philosophy and five-year plan.

 
view
download pdf
Industry Interview

Right on Time

Olga Alfonsova at PSI CRO AG discusses how to deliver clinical trials on time, as well as explaining her future goals.

 
view
download pdf
   
spacer



Published quarterly in
February, May,
August and November

News and Press Releases

Saneca to drive R&D Initiative following €1.5 million funding


More info >>

White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>

Industry Events

7th American Drug Delivery & Formulation Summit

28-29 August 2017, The Westin Copley Place Boston Hotel

Innovative solutions to the greatest challenges in pharmaceutical development
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement